NCT06339138CompletedNot Applicable
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing in Blood and Urine
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Mayo Clinic
- Enrollment
- 589
- Locations
- 1
- Primary Endpoint
- Identify novel methylated DNA markers in tissue for malignant renal and urothelial tumors
Study Overview
Brief Summary
This study is being done to collect blood, tissue and urine samples to identify a novel high quality methylated DNA marker in patients with renal tumors.
Detailed Description
PRIMARY OBJECTIVES:
I. In tissue, to discover and validate DNA methylation markers (MDMs) for detection of malignant renal and urothelial tumors.
II. In blood, to assess the accuracy of candidate MDMs from above for detection of malignant renal and urothelial tumors.
OUTLINE: This is an observational study.
Participants may undergo blood, urine, and tissue sample collection on study. Participants' medical records are also reviewed.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •CASE TISSUE:
- •Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, clear cell papillary RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma
- •Age >= 18 years
- •CASE BLOODS AND URINE:
- •Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma
- •Age >= 18 years
- •HEALTHY CONTROL BLOODS AND URINE:
- •Patients has undergone negative hematuria workups (defined as negative abdominal imaging and negative cystoscopy
- •Age >= 18 years
Exclusion Criteria
- •CASE TISSUE:
- •Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD)
- •The current target pathology is a recurrence
- •Patient has undergone any prior radiation therapy to target lesion prior to surgery
- •Patient has received chemotherapy class drugs in the 5 years prior to surgery
- •Patient has had any transplants prior to surgery
- •Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X
- •Patient has Nephritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease
- •RENAL CONTROL TISSUE:
- •Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD).
- •Patient has inflammation, atypia, or hyperplasia of the parenchyma
- •Patient has a current or past history of renal cancer.
- •Patient has undergone any prior radiation therapy to target lesion prior to surgery
- •Patient has received chemotherapy class drugs in the 5 years prior to surgery
- •Patient has had any transplants prior to surgery
- •Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X
- •Patient has Nephritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease
- •UROTHELIAL CONTROL TISSUE:
- •Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD)
- •Patient has inflammation, atypia, or hyperplasia of the urothelium
- •Patient has a current or past history of urothelial cancer
- •Patient has undergone any prior radiation therapy to target lesion prior to surgery
- •Patient has received chemotherapy class drugs in the 5 years prior to surgery
- •Patient has had any transplants prior to surgery
- •Patient has confirmed or presumed lynch
- •CASE BLOODS AND URINE:
- •Patient has known primary cancer outside of the kidney within the last 5 years prior to plasma and urine collection (not including basal cell or squamous cell skin cancers)
- •Patient has had surgery to completely or partially remove current target pathology
- •Patient has undergone any prior radiation therapy to target lesion prior to plasma and urine collection
- •Patient has received chemotherapy class drugs in the 5 years prior to plasma and urine collection
- •Patient has had any transplants prior to plasma and urine collection
- •Patient has confirmed or presumed lynch
- •Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD)
- •HEALTHY CONTROL BLOODS AND URINE:
- •Patient has known primary cancer outside of the urothelium within the last 5 years prior to plasma and urine collection (not including basal cell or squamous cell skin cancers)
- •Current target pathology is a recurrence
- •Patient has undergone prior radiation therapy in the 5 years prior to plasma and urine collection
- •Patient has received chemotherapy class drugs in the 5 years prior to plasma and urine collection
- •Patient has had any transplants prior to plasma and urine collection
- •Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD)
- •Patient has confirmed or presumed lynch
- •Gross urinary incontinence
- •Patient has undergone cystectomy
Arms & Interventions
Observational
Participants may undergo blood, urine, and tissue sample collection on study. Participants' medical records are also reviewed.
Intervention: Non-Interventional Study (Other)
Outcomes
Primary Outcomes
Identify novel methylated DNA markers in tissue for malignant renal and urothelial tumors
Time Frame: Baseline (at enrollment)
Assessed by the number of markers identified using unbiased whole methylome sequencing (RRBS). Top candidates will be validated in independent tissue. Potential markers will have relatively low background and a false discovery rate 20%.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of LiposarcomasAtypical Lipomatous TumorLiposarcomaNCT04224064Institut du Cancer de Montpellier - Val d'Aurelle158
Completed
Not Applicable
Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With HematuriaBladder CancerNCT05362539Mansoura University246
Recruiting
Not Applicable
A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)Hematopoietic and Lymphoid System NeoplasmMalignant Solid NeoplasmNCT06192875Mayo Clinic10,000
Active, not recruiting
Not Applicable
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver CancerResectable Hepatocellular CarcinomaNCT04856046Mayo Clinic36
Recruiting
Not Applicable
MeD-seq, a novel assay for genome-wide DNA methylation profiling in developing predictive biomarkers of gynaecological cancer and endometriosisall female genital cancersovarian cancer. uterine cancer and endometriosisvulva cancer10013364cervical cancerNL-OMON51586Erasmus MC, Universitair Medisch Centrum Rotterdam160